Fluzone Influenza Vaccine Descriptions
Sanofi Pasteur's Fluzone Quadrivalent influenza vaccine contains the 2 strains of influenza A and B identified for the current flu season. The Fluzone vaccine is given to people 6 months of age and older.
And the Fluzone High-Dose is a vaccine given to people 65 years of age and older that also contains 4 killed flu virus strains. Fluzone High-Dose contains four times the antigen (the part of the vaccine that helps your body build up protection against flu viruses) of standard-dose inactivated influenza vaccines. The higher dose of antigen in the vaccine is intended to give older people a better immune response and better protection against flu, says Sanofi.
For the 2021-2022 flu season in the Northern Hemisphere, the quadrivalent (four-component) egg-based vaccines protect against a second lineage of B viruses. U.S. Egg-Based influenza vaccines are recommended to contain the following A/Victoria/2570/2019 (H1N1)pdm09-like virus, A/Cambodia/e0826360/2020 (H3N2)-like virus, B/Washington/02/2019 (B/Victoria lineage)-like virus, and B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
"We are experiencing fast-growing demand for our vaccine in the U.S. and globally, given the 10 years of data demonstrating protection from flu and its related complications," said Elaine O'Hara, Head of North America Commercial Operations for Sanofi Pasteur, in a related press statement issued on June 17, 2021. "Our new facility will complement our existing capacities to produce enough high-dose vaccine for all people 65 and older in as many countries as possible this flu season and beyond, supporting the needs of healthcare providers and patients."
Sanofi Pasteur produces influenza vaccines each year across five international sites: Swiftwater (Pennsylvania, United States), Pearl River (New York, United States), Val-de-Reuil, Ocoyoacac (Mexico), and Shenzhen (China). As the largest manufacturer of influenza vaccines globally, Sanofi has been continuously investing to expand manufacturing capabilities and distributed more than 250 million doses of influenza vaccines globally in 2020.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.|
Fluzone Influenza Vaccine Indication
Fluzone Quadrivalent and Fluzone High-Dose vaccines help prevent influenza disease caused by influenza A and B strains contained in each vaccine.
Fluzone Quadrivalent is approved to help protect eligible people 6 months and older. Fluzone High-Dose is specifically formulated for people 65 years and older, containing 4 times the standard dose. It’s proven to be 24.2% more effective than the standard-dose Fluzone vaccine in preventing the flu.
Fluzone Influenza Vaccine Safety Information
Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be given to anyone who has had a severe allergic reaction to any vaccine component (including eggs or egg products for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent) or after a previous dose of the vaccine. In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be given to anyone who has had a severe allergic reaction after a previous dose of any influenza vaccine.
Fluzone Influenza Vaccine News
June 17, 2021 - The U.S. Food and Drug Administration Center for Biologics Evaluation and Research has approved Sanofi Pasteur, the vaccines global business unit of Sanofi, for an additional influenza manufacturing facility located in Swiftwater, PA.
March 8, 2021 - Certain patients have an increased risk of influenza infections and poor serologic response to standard influenza vaccination. A new study found tandem high-dose influenza vaccination leads to more robust and more durable seroprotection in high-risk patients.
October 7, 2020 - High-dose flu vaccine is in short supply in some places. If the high-dose vaccine is not available, the CDC recommends getting the regular dose.
Fluzone Influenza Vaccine Clinical Trials